Table 6.

Intra-tumoral and systemic therapy.

Agent	Class	Phase	Trial ID	Status on ClinicalTrials.gov (Accessed on 10 Ocober 2021)
Talimogene laherparepvec + pembrolizumab	modified oncolytic HSV 1 + anti-PD-1	II	NCT02965716	active, non recruiting
Talimogene laherparepvec + pembrolizumab	modified oncolytic HSV 1 + anti-PD-1	II	NCT04068181	active, non recruiting
CMP-001 + nivolumab	TLR9 agonist + anti-PD-1	II	NCT04698187	recruiting
CMP-001 + nivolumab	TLR9 agonist + anti-PD-1	II/III	NCT04695977	recruiting
PV-10 + pembrolizumab	small molecule autolytic immunotherapy + anti-PD-1	I/II	NCT02557321	recruiting

PD-1: Programmed death 1; HSV1: Herpes Simplex Virus 1; TLR9: Toll Like Receptor 9.